MD Anderson and Rigel partner to expand olutasidenib evaluation in AML and other cancers

MD Anderson and Rigel partner to expand olutasidenib evaluation in AML and other cancers
The University of Texas MD Anderson Cancer Center and Rigel Pharmaceuticals, Inc. today announced a multi-year strategic development collaboration to expand the...
The University of Texas MD Anderson Cancer Center and Rigel Pharmaceuticals, Inc. today announced a multi-year strategic development collaboration to expand the... Read More



Related Stories

See All